134 related articles for article (PubMed ID: 16213155)
1. Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees.
Pantsulaia I; Trofimov S; Kobyliansky E; Livshits G
Cytokine; 2005 Oct; 32(2):117-23. PubMed ID: 16213155
[TBL] [Abstract][Full Text] [Related]
2. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
3. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
[TBL] [Abstract][Full Text] [Related]
4. Human cytomegalovirus, Epstein-Barr virus and bone resorption-inducing cytokines in periapical lesions of deciduous teeth.
Yildirim S; Yapar M; Kubar A; Slots J
Oral Microbiol Immunol; 2006 Apr; 21(2):107-11. PubMed ID: 16476020
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
[TBL] [Abstract][Full Text] [Related]
6. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
7. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
9. [Pathophysiological significance and clinical utility of circulating osteoprotegerin].
Dovio A; Data V; Angeli A
Ann Ital Med Int; 2004; 19(1):8-19. PubMed ID: 15176704
[TBL] [Abstract][Full Text] [Related]
10. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.
Oh KW; Rhee EJ; Lee WY; Kim SW; Baek KH; Kang MI; Yun EJ; Park CY; Ihm SH; Choi MG; Yoo HJ; Park SW
Clin Endocrinol (Oxf); 2005 Jan; 62(1):92-8. PubMed ID: 15638876
[TBL] [Abstract][Full Text] [Related]
11. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
12. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
[TBL] [Abstract][Full Text] [Related]
13. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
[TBL] [Abstract][Full Text] [Related]
15. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.
Crisafulli A; Micari A; Altavilla D; Saporito F; Sardella A; Passaniti M; Raffa S; D'anneo G; Lucà F; Mioni C; Arrigo F; Squadrito F
Clin Sci (Lond); 2005 Oct; 109(4):389-95. PubMed ID: 15926884
[TBL] [Abstract][Full Text] [Related]
17. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
Dovio A; Data V; Angeli A
J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.
Zehnder AF; Kristiansen AG; Adams JC; Merchant SN; McKenna MJ
Laryngoscope; 2005 Jan; 115(1):172-7. PubMed ID: 15630389
[TBL] [Abstract][Full Text] [Related]
19. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]